Therapeutic Goods (Medicines—Remdesivir) (COVID-19 Emergency) Exemption 2020

Administered by Department of Health, Disability and Ageing

Legislation au F2020N00040 Not in force Notifiable Instrument

Legislation content

 

Therapeutic Goods (Medicines—Remdesivir) (COVID-19 Emergency) Exemption 2020

I, Caroline Edwards, as delegate of the Minister for Health, make the following exemption.

Dated 2 April 2020

Caroline Edwards

Acting Secretary

Department of Health

 

Contents

1  Name

2  Commencement

3  Authority

4  Definitions

5  Exemption

6  Conditions

 

 

1  Name

  This instrument is the Therapeutic Goods (MedicinesRemdesivir) (COVID-19 Emergency) Exemption 2020.

2  Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

The day this instrument is made.

2 April 2020

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under section 18A of the Therapeutic Goods Act 1989.

4  Definitions

Note: A number of expressions used in this instrument are defined in section 3 of the Act, including the following:

(a) manufacture;

(b) supply.

  In this instrument:

Act means the Therapeutic Goods Act 1989.

COVID-19 emergency means the public health emergency caused by the outbreak of the disease known as coronavirus disease (COVID-19).

Note: The World Health Organization declared the outbreak of COVID-19, formerly novel coronavirus (2019 nCoV), a Public Health Emergency of International Concern on 30 January 2020, and subsequently characterised the outbreak as a pandemic on 11 March 2020. On 18 March 2020, the Australian Government declared a human biosecurity emergency in Australia under the Biosecurity Act 2015.

Regulations means the Therapeutic Goods Regulations 1990.

specified therapeutic goods means a medicine to which each of the following paragraphs apply:

 (a) the medicine contains the active ingredient, remdesivir; and

 (b) the medicine does not contain any other active ingredient; and

 (c) the medicine is manufactured for intravenous infusion.

5  Exemption

 (1) The specified therapeutic goods are exempt from the operation of Division 2 of Part 3-2 of the Act in order to deal with the actual threat to public health caused by the COVID-19 emergency.

Note: Under paragraph 18A(2)(b) of the Act, the Minister may make an exemption under subsection 18A(1) only if satisfied that, in the national interest, the exemption should be made so that the goods can be made available urgently in Australia to deal with an actual threat to public health caused by an emergency that has occurred.

Period of exemption

 (2) This exemption takes effect on the commencement of this instrument and ceases to have effect on 31 January 2021.

6  Conditions

  This exemption is subject to the following conditions:

 (a) the specified therapeutic goods must only be imported, exported, manufactured or supplied by a person under a contract between the person and the Australian Government Department of Health for that purpose; and

 (b) the specified therapeutic goods must only be supplied in Australia for the prevention, treatment or alleviation of coronavirus (COVID-19) following advice from the Australian Government Department of Health; and

 (c) the person mentioned in paragraph (a) must keep records in relation to the importation, exportation, manufacture and supply of the relevant specified therapeutic goods; and

 (d) on request from the Secretary, the person mentioned in paragraph (a) must make the records mentioned in paragraph (c) available to the Secretary; and

 (e) the specified therapeutic goods must be stored and transported in a manner that ensures:

 (i) the security of the goods is appropriate to the level of risk that the goods pose to the public and environment; and

 (ii) the integrity of the condition of the goods is maintained.

Note 1: There are offences and civil penalty provisions in relation to goods exempt under section 18A, including:

(a) sections 20, 22 and 22AA (offences and civil penalties for breaching a condition of exemption);

(b) sections 30F and 30FA (offence and civil penalty for goods not conforming to standards);

(c) section 30H (offence for not keeping records);

(d) sections 35 and 35A (offence and civil penalty for manufacturing goods without a licence).

Note 2: There are other provisions in the Act that apply to goods exempt under section 18A, including:

(a) section 31AA (requirement to provide information to the Secretary);

(b) sections 39 and 41 (provisions relating to manufacturing goods);

(c) section 46A (provision enabling search of premises).

Note 3: Regulation 12AAB and Schedule 5B of the Regulations set out arrangements for the disposal of unused emergency goods for the purposes of section 30G of the Act.

 

Overview

The Therapeutic Goods (Medicines—Remdesivir) (COVID-19 Emergency) Exemption 2020 was enacted to address the urgent need for the availability of specific therapeutic goods in response to the public health emergency caused by the COVID-19 pandemic. This exemption was introduced under section 18A of the Therapeutic Goods Act 1989 by Caroline Edwards, as the delegate of the Minister for Health, to allow the importation, exportation, manufacture, and supply of specified therapeutic goods containing remdesivir, intended for intravenous infusion, to be used for the prevention, treatment, or alleviation of COVID-19 in Australia. The exemption was enacted to ensure that these therapeutic goods could be made available urgently to deal with the actual threat to public health caused by the COVID-19 emergency, with strict conditions governing their use, storage, transportation, and record-keeping to maintain public safety and the integrity of the goods. This measure was implemented to support the national response to the pandemic and ensure the availability of necessary medical treatments.

Scope and Application

The Therapeutic Goods (Medicines—Remdesivir) (COVID-19 Emergency) Exemption 2020 applies to a specific medicine containing the active ingredient remdesivir, which is intended for intravenous infusion and must not contain any other active ingredient. This exemption is granted under the authority of section 18A of the Therapeutic Goods Act 1989 to facilitate the urgent availability of these medicines in Australia during the COVID-19 emergency. The exemption applies nationally and is effective from the date of its creation, 2 April 2020, until 31 January 2021, subject to conditions that mandate the medicine be handled under a contract with the Australian Government Department of Health, used only for the prevention, treatment, or alleviation of COVID-19, and stored and transported securely. Records of importation, exportation, manufacture, and supply must be kept and made available upon request. The exemption does not extend to any other therapeutic goods not meeting these specific criteria.

Key Provisions

The main operative sections of this exemption are Sections 5 and 6. Section 5 exempts specified therapeutic goods, which are defined as medicines containing the active ingredient remdesivir, without any other active ingredient, and manufactured for intravenous infusion, from certain provisions of the Therapeutic Goods Act 1989 (the Act). This exemption is made to address the public health threat posed by the COVID-19 emergency. The exemption is effective from the date of the instrument's making, 2 April 2020, and will cease on 31 January 2021. The obligations and requirements imposed by this Act include that the specified therapeutic goods must only be imported, exported, manufactured, or supplied by a person under a contract with the Australian Government Department of Health. These goods must only be supplied in Australia for the prevention, treatment, or alleviation of COVID-19, following advice from the Department of Health. Additionally, the person responsible must keep records of the importation, exportation, manufacture, and supply of these goods, and must make these records available to the Secretary upon request. The goods must also be stored and transported in a manner that ensures their security and maintains the integrity of their condition. The Therapeutic Goods (Medicines—Remdesivir) (COVID-19 Emergency) Exemption 2020 includes several offences, penalties, and consequences for breach. For instance, breaching a condition of exemption, not conforming to standards, or not keeping records can result in offences and civil penalties as specified in sections 20, 22, 22AA, 30F, 30FA, and 30H of the Act. Manufacturing goods without a licence can also result in offences and civil penalties as per sections 35 and 35A of the Act. Furthermore, section 31AA requires the provision of information to the Secretary, and sections 39 and 41 relate to manufacturing goods, while section 46A enables the search of premises. Regulation 12AAB and Schedule 5B of the Regulations outline the arrangements for the disposal of unused emergency goods under section 30G of the Act.

Legal classification tags

Area of Law
Medical Law
Public Health Law
Instrument
Notifiable instrument
Concepts
Commencement Provisions
Exemptions & Exclusions
Reporting & Disclosure Obligations
Offence Provisions

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.